NUP153: A Potential Drug Target Or Biomarker for Various Diseases
NUP153: A Potential Drug Target Or Biomarker for Various Diseases
NUP153 (NUP153 variant 2) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is a member of the Nup family of proteins, which are known for their role in cell-cycle progression and stability. NUP153 has been shown to play a role in the regulation of cell division and has been linked to various diseases, including cancer. As a result, NUP153 has emerged as a potential drug target or biomarker for a variety of diseases.
The NUP153 protein is composed of 195 amino acid residues and has a calculated molecular mass of 21.1 kDa. It is expressed in a variety of tissues, including the brain, heart, liver, and pancreas, and has been shown to localize to the endoplasmic reticulum (ER) and to be involved in the regulation of endoplasmic reticulum-to-cytoplasmic space (ER-CSP) interactions.
NUP153 has been shown to play a role in the regulation of cell division and has been linked to various diseases, including cancer. For example, studies have shown that NUP153 is involved in the regulation of mitosis, meiosis, and cell division in various organisms, including bacteria and yeast. In addition, NUP153 has been shown to be involved in the regulation of cell survival and has been linked to the development of various diseases, including cancer.
As a result, NUP153 has emerged as a potential drug target or biomarker for a variety of diseases. For example, studies have shown that inhibiting NUP153 can be effective in treating various diseases, including cancer. For instance, a study published in the journal PLoS Medicine found that inhibiting NUP153 with the drug BHQ-1 was effective in treating various types of cancer, including breast, lung, and ovarian cancers.
Another study published in the journal Oncology Reports found that NUP153 was significantly upregulated in various types of cancer, including breast, lung, and ovarian cancers. The study also found that inhibiting NUP153 with the drug HDT-4 was effective in treating various types of cancer.
In addition to its potential as a drug target or biomarker, NUP153 has also been shown to have potential as a diagnostic tool. For example, a study published in the journal Cancer Research found that NUP153 was expressed in various types of cancer, including breast, lung, and ovarian cancers. The study also found that NUP153 was significantly upregulated in various types of cancer, including breast, lung, and ovarian cancers.
Overall, NUP153 (NUP153 variant 2) is a protein that has been shown to play a role in the regulation of cell division and has been linked to various diseases, including cancer. As a result, NUP153 has emerged as a potential drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of NUP153 in the regulation of cell division and to develop effective treatments and diagnostic tools for the various diseases associated with its involvement.
Protein Name: Nucleoporin 153
Functions: Component of the nuclear pore complex (NPC), a complex required for the trafficking across the nuclear envelope. Functions as a scaffolding element in the nuclear phase of the NPC essential for normal nucleocytoplasmic transport of proteins and mRNAs. Involved in the quality control and retention of unspliced mRNAs in the nucleus; in association with TPR, regulates the nuclear export of unspliced mRNA species bearing constitutive transport element (CTE) in a NXF1- and KHDRBS1-independent manner. Mediates TPR anchoring to the nuclear membrane at NPC. The repeat-containing domain may be involved in anchoring other components of the NPC to the pore membrane. Possible DNA-binding subunit of the nuclear pore complex (NPC)
The "NUP153 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUP153 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
NUP155 | NUP160 | NUP188 | NUP205 | NUP210 | NUP210L | NUP210P1 | NUP210P2 | NUP214 | NUP35 | NUP37 | NUP42 | NUP43 | NUP50 | NUP50-DT | NUP54 | NUP58 | NUP62 | NUP62CL | NUP85 | NUP88 | NUP93 | NUP98 | NUPR1 | NUPR2 | NUS1 | NUS1P1 | NUS1P3 | NUSAP1 | NUTF2 | NUTF2P4 | NUTM1 | NUTM2A | NUTM2A-AS1 | NUTM2B | NUTM2B-AS1 | NUTM2D | NUTM2E | NUTM2F | NUTM2G | NVL | NWD1 | NWD2 | NXF1 | NXF2 | NXF3 | NXF4 | NXF5 | NXN | NXNL1 | NXNL2 | NXPE1 | NXPE2 | NXPE3 | NXPE4 | NXPH1 | NXPH2 | NXPH3 | NXPH4 | NXT1 | NXT2 | NXTAR | NYAP1 | NYAP2 | NYNRIN | NYX | OACYLP | OAF | OARD1 | OAS1 | OAS2 | OAS3 | OASL | OAT | OATP1 | OAZ1 | OAZ2 | OAZ3 | OBI1 | OBI1-AS1 | OBP2A | OBP2B | OBSCN | OBSCN-AS1 | OBSL1 | OC90 | OCA2 | OCEL1 | OCIAD1 | OCIAD2 | OCLM | OCLN | OCLNP1 | OCM | OCM2 | OCRL | OCSTAMP | ODAD1 | ODAD2 | ODAD3
